

Additional File 5: Supplemental References

1. Børresen AL, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, et al. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. *Proc Natl Acad Sci U S A*. 1991 Oct;88(19):8405–9.
2. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. *Cancer Res*. 1992 Oct;52(19):5291–8.
3. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, et al. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. *J Natl Cancer Inst*. 1992 Feb;84(4):246–52.
4. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. *Jpn J Cancer Res*. 1993 Apr;84(4):394–401.
5. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL. Prognostic significance of TP53 alterations in breast carcinoma. *Br J Cancer*. 1993 Sep;68(3):540–8.
6. Thorlacius S, Børresen AL, Eyfjörd JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. *Cancer Res*. 1993 Apr;53(7):1637–41.
7. Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, et al. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. *Cancer Res*. 1994 Aug;54(15):4200–6.
8. Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. *Lancet (London, England)*. 1994 May;343(8907):1195–7.
9. Umekita Y, Kobayashi K, Saheki T, Yoshida H. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. *Jpn J Cancer Res*. 1994 Aug;85(8):825–30.
10. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. *Int J cancer*. 1994 May;57(4):498–503.
11. Saitoh S, Cunningham J, De Vries EM, McGovern RM, Schroeder JJ, Hartmann A, et al. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. *Oncogene*. 1994 Oct;9(10):2869–75.
12. Hartmann A, Rosanelli G, Blaszyk H, Cunningham JM, McGovern RM, Schroeder JJ, et al. Novel pattern of P53 mutation in breast cancers from Austrian women. *J Clin Invest*. 1995 Feb;95(2):686–9.

13. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. *Cancer Res.* 1995 Apr;55(7):1485–90.
14. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. *Oncogene.* 1995 Feb;10(4):681–8.
15. Karameris AM, Worthy E, Gorgoulis VG, Quezado M, Anastassiades OT. p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. *J Pathol.* 1995 Aug;176(4):361–72.
16. Sato T, Okazaki A, Okazaki M, Takahashi S, Hirata K. Detection of p53 gene mutations in aspiration biopsy specimens from suspected breast cancers by polymerase chain reaction-single strand conformation polymorphism analysis. *Jpn J Cancer Res.* 1995 Feb;86(2):140–5.
17. Thorlacius S, Thorgilsson B, Björnsson J, Tryggvadottir L, Børresen AL, Ogmundsdottir HM, et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. *Eur J Cancer.* 1995 Oct;31A(11):1856–61.
18. Blaszyk H, Hartmann A, Tamura Y, Saitoh S, Cunningham JM, McGovern RM, et al. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. *Oncogene.* 1996 Nov;13(10):2159–66.
19. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. *Nat Med.* 1996 Jul;2(7):811–4.
20. Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olafsdottir K, Agnarsson BA, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. *Br J Cancer.* 1996 Aug;74(4):555–61.
21. Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, et al. High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. *Br J Cancer.* 1996 Apr;73(8):896–901.
22. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. *Proc Natl Acad Sci U S A.* 1996 Feb;93(3):1093–6.
23. Chakravarty G, Redkar A, Mitra I. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. *Br J Cancer.* 1996 Oct;74(8):1181–7.
24. Lou MA, Tseng SL, Chang SF, Yue CT, Chang BL, Chou CH, et al. Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. *Br J Cancer.* 1997;75(5):746–51.
25. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. *APMIS.* 1997 Feb;105(2):121–30.

26. Zelada-Hedman M, Børresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. *Br J Cancer*. 1997;75(8):1201–4.
27. Günther T, Schneider-Stock R, Rys J, Niezabitowski A, Roessner A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. *J Cancer Res Clin Oncol*. 1997;123(7):388–94.
28. Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. *Br J Cancer*. 1998 Apr;77(7):1130–6.
29. Lavarino C, Corletto V, Mezzelani A, Della Torre G, Bartoli C, Riva C, et al. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. *Br J Cancer*. 1998;77(1):125–30.
30. Williams C, Norberg T, Ahmadian A, Pontén F, Bergh J, Inganäs M, et al. Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. *Clin Chem*. 1998 Mar;44(3):455–62.
31. Wernert N, Hügel A, Löcherbach C. [Genetic alterations in the fibroblastic stroma of invasive colon and breast carcinomas]. *Verh Dtsch Ges Pathol*. 1998;82:317–21.
32. Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. *Eur J Cancer*. 1999 Mar;35(3):398–405.
33. Gentile M, Bergman Jungeström M, Olsen KE, Söderkvist P, Wingren S. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. *Eur J Cancer*. 1999 Aug;35(8):1202–7.
34. Tanyi J, Tory K, Bánkfalvi A, Shröder W, Rath W, Füzesi L. Analysis of p53 mutation and cyclin D1 expression in breast tumors. *Pathol Oncol Res*. 1999;5(2):90–4.
35. Tomita S, Muto Y, Kusano T, Toda T. [Genetic alterations in human malignant tumor]. *Rinsho Byori*. 1999 Jan;47(1):20–6.
36. Patrinos GP, Garinis G, Kounelis S, Kouri E, Menounos P. A novel 23-bp deletion in exon 5 of the p53 tumor suppressor gene. *J Mol Med (Berl)*. 1999 Sep;77(9):686–9.
37. Maitra A, Tavassoli FA, Albores-Saavedra J, Behrens C, Wistuba II, Bryant D, et al. Molecular abnormalities associated with secretory carcinomas of the breast. *Hum Pathol*. 1999 Dec;30(12):1435–40.
38. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. *Clin cancer Res an Off J Am Assoc Cancer Res*. 2000 Oct;6(10):3923–31.
39. Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis EP. p53 gene mutation, tumor p53 protein overexpression, and serum p53

autoantibody generation in patients with breast cancer. *Clin Biochem.* 2000 Feb;33(1):53–62.

40. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. *Clin cancer Res an Off J Am Assoc Cancer Res.* 2000 Jan;6(1):50–6.
41. Gudlaugsdottir S, Sigurdardottir V, Snorraddottir M, Jonasson JG, Ogmundsdottir H, Eyfjord JE. P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. *Diagn Cytopathol.* 2000 May;22(5):268–74.
42. Oh SJ, Jung JY, Shim SS, Im MY, Kim HD, Chung SY, et al. Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function. *Mol Cells.* 2000 Jun;10(3):275–80.
43. Kannan K, Krishnamurthy J, Feng J, Nakajima T, Tsuchida N, Shanmugam G. Mutation profile of the p53, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. *Int J Oncol.* 2000 Nov;17(5):1031–5.
44. Kang JH, Kim SJ, Noh DY, Choe KJ, Lee ES, Kang HS. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. *J Mol Med (Berl).* 2001 Nov;79(11):648–55.
45. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. *Cancer Res.* 2001 Mar;61(6):2505–12.
46. Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, et al. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. *Breast Cancer Res Treat.* 2001 May;67(1):1–8.
47. Buzin CH, Tang SH, Cunningham JM, Shibata A, Ross RK, Hartmann A, et al. Low frequency of p53 gene mutations in breast cancers of Japanese-American women. *Nutr Cancer.* 2001;39(1):72–7.
48. Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, et al. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. *Lab Invest.* 2001 Apr;81(4):573–9.
49. Stenmark-Askmal M, Gentile M, Wingren S, Ståhl O. Protein accumulation and gene mutation of p53 in bilateral breast cancer. South-East Sweden Breast Cancer Group. *Acta Oncol.* 2001;40(1):56–62.
50. Wang X, Mori I, Tang W, Yang Q, Nakamura M, Nakamura Y, et al. Metaplastic carcinoma of the breast: p53 analysis identified the same point mutation in the three histologic components. *Mod Pathol an Off J United States Can Acad Pathol Inc.* 2001 Nov;14(11):1183–6.
51. Conway K, Edmiston SN, Cui L, Drouin SS, Pang J, He M, et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. *Cancer Res.* 2002 Apr;62(7):1987–95.
52. Langerød A, Bukholm IRK, Bregård A, Lønning PE, Andersen TI, Rognum TO, et al. The TP53 codon 72 polymorphism may affect the

function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. *Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol.* 2002 Dec;11(12):1684–8.

53. Tessitore A, Di Rocco ZC, Cannita K, Ricevuto E, Toniato E, Tosi M, et al. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. *Genes Chromosomes Cancer.* 2002 Sep;35(1):86–91.
54. Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM, et al. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. *Int J cancer.* 2002 Nov;102(2):117–28.
55. Nagai MA, Schaer Barbosa H, Zago MA, Araújo Silva WJ, Nishimoto IN, Salaorni S, et al. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. *Int J Oncol.* 2003 Jul;23(1):189–96.
56. Bukholm IRK, Husdal A, Nesland JM, Langerød A, Bukholm G. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. *Breast Cancer Res Treat.* 2003 Jul;80(2):199–206.
57. Geisler S, Børresen-Dale A-L, Johnsen H, Aas T, Geisler J, Akslen LA, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. *Clin cancer Res an Off J Am Assoc Cancer Res.* 2003 Nov;9(15):5582–8.
58. Sekido Y, Umemura S, Takekoshi S, Suzuki Y, Tokuda Y, Tajima T, et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. *Int J Oncol.* 2003 Jun;22(6):1225–32.
59. Sensi E, Tancredi M, Aretini P, Cipollini G, Naccarato AG, Viacava P, et al. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. *Breast Cancer Res Treat.* 2003 Nov;82(1):1–9.
60. Reifemberger J, Rauch L, Beckmann MW, Megahed M, Ruzicka T, Reifemberger G. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. *Br J Dermatol.* 2003 May;148(5):1040–6.
61. Chen F-M, Hou M-F, Wang J-Y, Chen T, Chen DCP, Huang S-Y, et al. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. *Cancer Lett.* 2004 Apr;207(1):59–67.
62. Jong Y-J, Li L-H, Tsou M-H, Chen Y-J, Cheng SH, Wang-Wuu S, et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. *Cancer Genet Cytogenet.* 2004 Jan;148(1):55–65.
63. Lien H-C, Lin C-W, Mao T-L, Kuo S-H, Hsiao C-H, Huang C-S. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. *J Pathol.* 2004 Oct;204(2):131–9.

64. Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. *Breast Cancer Res Treat.* 2004 Nov;88(2):177–86.
65. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. *Am J kidney Dis Off J Natl Kidney Found.* 2004 Apr;43(4):e11-7.
66. Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. *J Pathol.* 2005 Sep;207(1):14–9.
67. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. *Cancer Lett.* 2005 May;222(1):57–65.
68. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res.* 2006;
69. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. *J Natl Cancer Inst.* 2006 Jul;98(13):911–9.
70. Han B, Mori I, Nakamura M, Wang X, Ozaki T, Nakamura Y, et al. Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis. *Pathol Int.* 2006 Apr;56(4):211–6.
71. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IRK, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. *Breast Cancer Res.* 2007;9(3):R30.
72. Ooe A, Kato K, Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. *Breast Cancer Res Treat.* 2007 Mar;101(3):305–15.
73. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. *N Engl J Med.* 2007 Dec;357(25):2543–51.
74. Eachkoti R, Hussain I, Afroze D, Aejaziz S, Jan M, Shah ZA, et al. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. *Cancer Lett.* 2007 Apr;248(2):308–20.
75. Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, et al. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. *Int J cancer.* 2008 Jun;122(12):2761–6.
76. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. *PLoS One.* 2008 Aug;3(8):e3062.

77. Suspitsin EN, Due EU, Vu P, Hirvonen A, Børresen-Dale A-L, Imyanitov EN. TP53 mutations in synchronous and metachronous bilateral breast carcinomas. Vol. 184, *Cancer genetics and cytogenetics*. United States; 2008. p. 119–21.
78. Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, et al. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCA1 from BRCA2-linked cases. *Mod Pathol an Off J United States Can Acad Pathol Inc*. 2008 Oct;21(10):1262–70.
79. Zhou W, Muggerud AA, Vu P, Due EU, Sørli T, Børresen-Dale A-L, et al. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. *Mol Oncol*. 2009 Jun;3(3):214–9.
80. Ochs-Balcom HM, Marian C, Nie J, Brasky TM, Goerlitz DS, Trevisan M, et al. Adiposity is associated with p53 gene mutations in breast cancer. *Breast Cancer Res Treat [Internet]*. 2015;153(3):635–45. Available from: <https://doi.org/10.1007/s10549-015-3570-5>
81. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012 Oct;490(7418):61–70.
82. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature*. 2012 Jun;486(7403):405–9.
83. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012 May;486(7403):400–4.
84. Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nat Commun*. 2016 May;7:11479.
85. Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, et al. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. *PLoS One*. 2018;13(9):e0203495.
86. Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. *Nat Commun*. 2018 Apr;9(1):1725.
87. Yap Y-S, Singh AP, Lim JHC, Ahn J-H, Jung K-H, Kim J, et al. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. *NPJ breast cancer*. 2018;4:19.
88. Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, et al. Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. *Int J cancer*. 2018 May;142(9):1890–900.
89. Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren C, et al. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. *Ann Transl Med*. 2019;
90. Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Sanni A, et al. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. *Int J cancer*. 2019 Dec;145(12):3321–33.

91. Yi D, Xu L, Luo J, You X, Huang T, Zi Y, et al. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study. *Hum Genomics*. 2019 Jan;13(1):4.
92. Chang C-S, Kitamura E, Johnson J, Bollag R, Hawthorn L. Genomic analysis of racial differences in triple negative breast cancer. *Genomics*. 2019 Dec;111(6):1529–42.
93. Powers J, Pinto EM, Barnoud T, Leung JC, Martynyuk T, Kossenkov A V, et al. A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Res*. 2020 Sep;80(17):3732–44.
94. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadij J, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. *Hum Mutat*. 2016;
95. Slovackova J, Grochova D, Navratilova J, Smarda J, Smardova J. Transactivation by temperature-dependent p53 mutants in yeast and human cells. *Cell Cycle*. 2010 Jun;9(11):2141–8.
96. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, et al. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. *Mol Cancer Res*. 2010 May;8(5):701–16.
97. Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN. [Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma]. *Mol Biol (Mosk)*. 2017;51(1):64–72.
98. Li C-L, Yeh K-H, Liu W-H, Chen C-L, Chen D-S, Chen P-J, et al. Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor- α in female hepatocellular carcinoma. *Int J cancer*. 2015 Feb;136(4):761–70.
99. Gonin-Laurent N, Gibaud A, Huygue M, Lefèvre SH, Le Bras M, Chauveinc L, et al. Specific TP53 mutation pattern in radiation-induced sarcomas. *Carcinogenesis*. 2006 Jun;27(6):1266–72.
100. O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL. Comparison of the effect of mutant and wild-type p53 on global gene expression. *Cancer Res*. 2004 Nov;64(22):8199–207.
101. Christgen M, Noskowicz M, Heil C, Schipper E, Christgen H, Geffers R, et al. IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. *Lab Invest*. 2012 Nov;92(11):1635–47.
102. Göhler T, Jäger S, Warnecke G, Yasuda H, Kim E, Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. *Nucleic Acids Res*. 2005;33(3):1087–100.
103. Bartussek C, Naumann U, Weller M. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. *Exp Cell Res*. 1999 Dec;253(2):432–9.
104. Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. *Proc Natl Acad*

Sci U S A. 2006 Oct;103(41):15056–61.

105. Kang HJ, Chun S-M, Kim K-R, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. *PLoS One*. 2013;8(8):e72609.
106. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. *Oncogene*. 2003 Aug;22(34):5252–60.
107. Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, et al. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. *Cancer Res*. 1999 Oct;59(19):4765–9.
108. Barta JA, Pauley K, Kossenkov A V, McMahon SB. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. *Carcinogenesis*. 2020 Mar;41(1):67–77.
109. Cardellino U, Ciribilli Y, Andreotti V, Modesto P, Menichini P, Fronza G, et al. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach. *Mutagenesis*. 2007 Nov;22(6):417–23.
110. Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. *Cancers (Basel)*. 2018 Dec;11(1).
111. Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. *Biochim Biophys Acta*. 2013 Mar;1830(3):2790–7.
112. Xie X, Lozano G, Siddik ZH. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. *Oncogene*. 2016 Sep;35(36):4798–806.
113. Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. *Mol Cell Biol*. 1998 Jul;18(7):3692–8.
114. Solomon H, Buganim Y, Kogan-Sakin I, Pomeranec L, Assia Y, Madar S, et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. *J Cell Sci*. 2012 Jul;125(Pt 13):3144–52.
115. West AN, Ribeiro RC, Jenkins J, Rodriguez-Galindo C, Figueiredo BC, Kriwacki R, et al. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. *Cancer Res*. 2006 May;66(10):5056–62.
116. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu W, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. *Blood*. 2012 Nov;120(19):3986–96.
117. Mullany LK, Wong K-K, Marciano DC, Katsonis P, King-Crane ER, Ren YA, et al. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. *Neoplasia*. 2015 Oct;17(10):789–803.

118. Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. *Proc Natl Acad Sci U S A*. 2003 Jul;100(14):8424–9.
119. Ahn J, Poyurovsky M V, Baptiste N, Beckerman R, Cain C, Mattia M, et al. Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. *Cell Cycle*. 2009 May;8(10):1603–15.
120. Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C, et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. *Oncotarget*. 2012 Feb;3(2):132–43.
121. Suchánková J, Legartová S, Ručková E, Vojtěšek B, Kozubek S, Bárťová E. Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after γ -irradiation that depleted MDC1 protein in specific TP53 mutants. *Histochem Cell Biol*. 2017 Sep;148(3):239–55.
122. Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, et al. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. *Sci Rep*. 2019 Nov;9(1):17050.
123. Lai J-C, Cheng Y-W, Goan Y-G, Chang JT, Wu T-C, Chen C-Y, et al. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. *DNA Repair (Amst)*. 2008 Aug;7(8):1352–63.
124. Friedler A, Veprintsev DB, Hansson LO, Fersht AR. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. *J Biol Chem*. 2003 Jun;278(26):24108–12.
125. Tsuchiya K. [Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant]. *Hokkaido Igaku Zasshi*. 2000 Jul;75(4):265–74.
126. Dong P, Tada M, Hamada J-I, Nakamura A, Moriuchi T, Sakuragi N. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. *Clin Exp Metastasis*. 2007;24(6):471–83.
127. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, et al. Screening the p53 status of human cell lines using a yeast functional assay. *Mol Carcinog*. 1997 Aug;19(4):243–53.
128. Pavlova S, Mayer J, Koukalova H, Swardova J. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. *Int J Oncol*. 2003 Jul;23(1):121–31.
129. Zerdoumi Y, Lanos R, Raad S, Flaman J-M, Bougeard G, Frebourg T, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. *Hum Mol Genet*. 2017 Jul;26(14):2591–602.
130. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. *Oncotarget*. 2014 Oct;5(19):8879–92.

131. Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, et al. A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. *Elife*. 2017 Aug;6.
132. Jia S, Zhao L, Tang W, Luo Y. The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. *Int J Biol Sci*. 2012;8(5):596–605.
133. Lokshin M, Li Y, Gaididon C, Prives C. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. *Nucleic Acids Res*. 2007;35(1):340–52.
134. Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. *Leukemia*. 2005 Aug;19(8):1459–65.
135. Kramer AC, Weber J, Zhang Y, Tolar J, Gibbens YY, Shevik M, et al. TP53 Modulates Oxidative Stress in Gata1(+) Erythroid Cells. *Stem cell reports*. 2017 Feb;8(2):360–72.
136. Quinn EA, Maciaszek JL, Pinto EM, Phillips AH, Berdy D, Khandwala M, et al. From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. *Cold Spring Harb Mol case Stud*. 2019 Aug;5(4).
137. Jagosova J, Pitrova L, Slovackova J, Ravcukova B, Smarda J, Smardova J. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells. *Int J Oncol*. 2012 Sep;41(3):1157–63.
138. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. *J Pathol*. 2005 Nov;207(3):251–9.
139. Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, et al. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. *Cancer Res*. 2002 May;62(10):2897–905.
140. Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A, et al. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. *Biochem Biophys Res Commun*. 2012 Nov;428(1):6–10.
141. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. *Carcinogenesis*. 2007 Feb;28(2):289–98.
142. Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan Y-C, et al. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. *Hum Mutat*. 2014 May;35(5):575–84.
143. Ko J-L, Chiao M-C, Chang S-L, Lin P, Lin J-C, Sheu G-T, et al. A novel p53 mutant retained functional activity in lung carcinomas. *DNA Repair (Amst)*. 2002 Sep;1(9):755–62.

144. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. *Oncogene*. 1998 May;16(19):2527–39.
145. Buzek J, Latonen L, Kurki S, Peltonen K, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. *Nucleic Acids Res*. 2002 Jun;30(11):2340–8.
146. Nouredine MA, Menendez D, Campbell MR, Bandele OJ, Horvath MM, Wang X, et al. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. *PLoS Genet*. 2009 May;5(5):e1000462.
147. Wang B, Niu D, Lam TH, Xiao Z, Ren EC. Mapping the p53 transcriptome universe using p53 natural polymorphs. *Cell Death Differ*. 2014 Apr;21(4):521–32.
148. Menendez D, Inga A, Resnick MA. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. *Mol Cell Biol*. 2006 Mar;26(6):2297–308.
149. Zhou R, Xu A, Wang D, Zhu D, Mata H, Huo Z, et al. A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. *Stem Cell Res*. 2018 Mar;27:131–5.
150. Lang V, Pallara C, Zabala A, Lobato-Gil S, Lopitz-Otsoa F, Farrás R, et al. Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. *Mol Oncol*. 2014 Jul;8(5):1026–42.
151. Kamada R, Nomura T, Anderson CW, Sakaguchi K. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. *J Biol Chem*. 2011 Jan;286(1):252–8.
152. Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T, et al. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. *Oncogene*. 2005 Oct;24(46):6976–81.